This event has concluded, but exciting conferences are happening worldwide — explore upcoming events in your field and stay ahead with the latest insights and networking opportunities. Subscribe to our newsletter.

3rd Cell Therapy Potency Assay Summit

92 92 people viewed this event.

Determining MoA and Satisfying Regulatory Requirements

In the dynamic cell therapy landscape, the challenge of potency assay development looms large, as exemplified by clinical holds experienced by Mesoblast and Verve Therapeutics in recent years.

Time: 8:00 am – 5:00 pm

Venue details: The Colonnade, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States

Prices: USD 2599.00 – USD 5896.00

Speakers: Amanda Lee, Senior Manager, Regulatory Affairs, Atara Biotherapeutics Inc., Benjamin Espen, Principal Quality Engineer, Avobis Bio, Chien-Chung Chen, Director, Analytical Development, Cabaletta Bio, Christopher Kloss, Senior Scientist, Johnson and Johnson, Christopher Rold, Vice President, Vector Development, Analytical Development and Quality Control, Adicet Bio Inc., Christopher Storbeck, Senior Scientific Evaluator, Health Canada, Chui Yu Lau, Associate Scientist, Century Therapeutics, Darren Kamikura, Director, Potency and Functional Characterization, Bristol Myers Squibb, David Dilworth, Senior Scientist, Assay Development, BlueRock Therapeutics, and more.

Event Organizer - Hanson Wade

Event Website
 

Date

19–21 March 2024
 

City

 

Country

United States of America
 

Topic Area

Health and Medicine

Share With Colleagues